The real test begins for Hong Kong’s new drug regulator

A number of important things must fall into place to flesh out a vision of Hong Kong as a biotech hub with a key role in developing affordable access to the latest drugs and other medical products. With the appointment of Dr Li Zili as controller of the Hong Kong Centre for Medical Products Regulation (CMPR), there …

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.